Health and Healthcare
Why Catalyst Bio Nearly Tripled
Published:
Last Updated:
Catalyst Biosciences Inc. (NASDAQ: CBIO) saw its shares practically triple in Tuesday’s session after the company announced a critical regulatory approval. The company reported that the Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New Drug Application (IND) for CB 2679d/ISU304, which works to treat individuals with hemophilia.
Hemophilia is a serious bleeding disorder that results in spontaneous bleeding episodes, as well as substantially prolonged bleeding times upon injury.
In terms of the drug, it is a highly potent next-generation coagulation Factor IX variant, has demonstrated the potential to normalize human Factor IX levels with a daily subcutaneous injection in preclinical studies. In simpler terms, CB2679d/ISU304 works to inhibit blood loss and can be used as a preventative treatment to individuals with hemophilia.
Catalyst’s collaborator, ISU Abxis, plans to initiate a Phase 1/2 proof-of-concept study in individuals with severe hemophilia B in the second quarter of 2017. After this Phase 1/2 study, ISU Abxis has an option for exclusive commercial rights in South Korea and a profit share on ex-South Korean commercialization. However, Catalyst would retain full development and commercial rights for the drug outside of South Korea.
Nassim Usman, Ph.D., president and CEO of Catalyst Bio, commented:
We are very pleased with the progress we and our collaborator ISU Abxis have made in advancing this Factor IX candidate towards the clinic and we look forward to the initiation of a Phase 1/2 clinical trial next quarter. We believe that stopping bleeding is good, but preventing bleeding is better. CB 2679d/ISU304 has the properties required, including high potency, to allow for daily subcutaneous injection with the potential to achieve stable and normal Factor IX clotting levels.
Shares of Catalyst Bio were trading up 196% at $15.24 on Tuesday, with a consensus analyst price target of $24.50 and a 52-week trading range of $0.45 to $18.88.
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
